The market is getting killed so anything in the green today is good. Two Orphan Drug Designations from the FDA would have a significant impact on the share price and open up business development conversations with BP. Anticipation for Lympro data should start to take hold.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links